Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 4;38(1):110172.
doi: 10.1016/j.celrep.2021.110172.

Ebola virus delta peptide is an enterotoxin

Affiliations
Free article

Ebola virus delta peptide is an enterotoxin

Lilia I Melnik et al. Cell Rep. .
Free article

Abstract

During the 2013-2016 West African (WA) Ebola virus (EBOV) outbreak, severe gastrointestinal symptoms were common in patients and associated with poor outcome. Delta peptide is a conserved product of post-translational processing of the abundant EBOV soluble glycoprotein (sGP). The murine ligated ileal loop model was used to demonstrate that delta peptide is a potent enterotoxin. Dramatic intestinal fluid accumulation follows injection of biologically relevant amounts of delta peptide into ileal loops, along with gross alteration of villous architecture and loss of goblet cells. Transcriptomic analyses show that delta peptide triggers damage response and cell survival pathways and downregulates expression of transporters and exchangers. Induction of diarrhea by delta peptide occurs via cellular damage and regulation of genes that encode proteins involved in fluid secretion. While distinct differences exist between the ileal loop murine model and EBOV infection in humans, these results suggest that delta peptide may contribute to EBOV-induced gastrointestinal pathology.

Keywords: Ebola virus; Ebola virus disease gastrointestinal pathology; cell damage response; cell membrane transport and exchange; cell survival pathways; cellular fluid excretion; delta peptide; enterotoxin; transcriptomic analysis.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Dr. Garry is co-founder of Zalgen Labs, a biotechnology company that develops countermeasures for emerging viruses.

Publication types